

# Global Research on the Impact of Dermatological Diseases (GRIDD)

Trialonis-Suthakharan N<sup>1</sup>, Pattinson R.<sup>2</sup>, Bundy C.<sup>2</sup>, Augustin M<sup>1</sup>

<sup>1</sup>German Center for Health Services Research in Dermatology (CVderm), University Medical Hamburg, Germany | <sup>2</sup>School of Health Sciences, Cardiff University, United Kingdom.

## GRIDD


The Global Research on the Impact of Dermatological Diseases (GRIDD) project aims to develop a new methodology along with a novel, comprehensive global impact measure called PRIDD: Patient-Reported Impact of Dermatological Diseases. GRIDD is the first global patient-initiated and patient-led impact research study in dermatology. PRIDD data will reveal the true impact of dermatology diseases from the patient perspective.



## BACKGROUND


Existing patient-reported outcome measures (PROMs) and metrics (e.g. DALYs) in dermatology arguably underestimate the true impact of dermatological conditions on patients' lives. This impacts treatment decision-making and resource allocations. To fully understand the impact of dermatological conditions, information must be obtained from patients. The PRIDD patient-impact measure will produce patient-derived data needed for a wide range of purposes including research, advocacy, better treatments and raising dermatology in the disease rankings. GRIDD is a project of the International Alliance of Dermatology Patient Organizations (IADPO, also known as GlobalSkin) and its research is co-led by the University Medical Center Hamburg and Cardiff University.

## METHODOLOGY: MULTIPHASE PROJECT




## GLOBALSKIN NETWORK

A global network consisting of 170+ patient organisations in 54 countries with 60+ disease areas has been established by GlobalSkin.



## RESULTS II

Systematic review of 36 PROMs revealed that there is no existing specific measure of impact in dermatology. Furthermore, NO measurement tool currently meets the standards recommended. Evidence for content validity was very weak. This indicates a clear need for a **new patient-impact measurement tool** that will effectively challenge the current burden of disease estimates.




## METHODOLOGY

### COSMIN

The COSMIN methodology was followed to evaluate the measures identified. The COSMIN 'Risk of Bias Checklist' is the gold standard, validated critical appraisal tool designed for validating and reporting the methodological quality of studies of health measures for systematic review.



Each measure was evaluated by its methodological quality and by its measurement properties. A standardised recommendation for use or further validation for each instrument was made.



## DISCUSSION

GRIDD adds new knowledge to existing information about the impact of living with dermatological conditions. PRIDD, developed using both qualitative and quantitative methods, will produce much needed patient impact data. It will raise global awareness, locally, regionally and internationally, across conditions. This information will influence better decision-making and resource allocation for clinicians and policy makers and ultimately benefit patients. **The project is currently in Phase 3, the Delphi survey.**

*The GRIDD methodology can be a replicable model for pediatric dermatology as well as for other disease conditions beyond dermatology. With additional research, the PRIDD measure could be developed to provide the true child/youth patient impact of living with a dermatological disease.*

